Johnson & Johnson looking to buy Ollin Biosciences for up to US$3.4bil

NEW YORK: Johnson & Johnson is poised to buy privately held eye disease drug developer Ollin Biosciences for up to US$3.4 billion, the Financial Times reported on Sunday, citing people familiar with the matter.

Under the terms of the deal being discussed, J&J could pay Ollin’s backers US$2.2 billion upfront in cash and a further US$1.2 billion in potential milestone payments, the FT reported.

Reuters could not immediately verify the report.